Clinical Trial Update: Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) [Phase 2]

View source ↗

Summary

This document reports the completed Phase II trial results for bevacizumab plus erlotinib in patients with recurrent malignant glioma, including glioblastoma an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-05-13